Tumor growth and metastasis depend on angiogenesis; therefore, efforts are made to
develop specific angiogenic inhibitors. Halofuginone (HF) is a potent inhibitor of collagen …

Halofuginone, an inhibitor of collagen α1 (I) gene expression was used for the treatment of
subcutaneously implanted C6 glioma tumors. Halofuginone had no effect on the growth of …

At present, halofuginone is the only known inhibitor of collagen synthesis that is type
specific. Halofuginone was found to inhibit collagen α1 (I) gene expression and collagen …

Halofuginone inhibits fibrosis by decreasing type I collagen synthesis and tumor growth
through an anti-angiogenic mechanism. In vitro data suggested that halofuginone inhibited …

Halofuginone, an inhibitor of collagen synthesis, appears to be a promising antitumoral drug
in preclinical studies. We used a relevant rat model of autochthonous, chemically induced …

Halofuginone has recently been shown to inhibit tumor progression of various types of
cancers. The antitumoral effect was associated with decreased tumor angiogenesis rather …

Background Halofuginone (HF) is a low-molecular-weight alkaloid that has been
demonstrated to interfere with Metalloproteinase-2 (MMP-2) and Tumor Growth Factor-β …

Purpose: Halofuginone (HF) inhibits synthesis of collagen type I and matrix
metalloproteinase-2 and is being considered for clinical evaluation as an antineoplastic …

We have previously demonstrated that halofuginone, a low molecular weight quinazolinone
alkaloid, is a potent inhibitor of collagen α1 (I) and matrix metalloproteinase 2 (MMP‐2) gene …

TGF-β derived from bone fuels melanoma bone metastases by inducing tumor secretion of
prometastatic factors that act on bone cells to change the skeletal microenvironment …